Transforming Drug Discovery and Development:The Impact of Artificial Intelligence
Bibliographic record
Abstract
Artificial intelligence (AI) is revolutionizing the drug development process, transforming the entire process. AI can help researchers find drug candidates faster, conduct clinical trials more efficiently, improve manufacturing processes, and expand market access options. It can speed up the first phases of drug discovery by facilitating quick screening of candidate compounds by anticipating interactions between molecules and target proteins. AI also plays a significant role in the successful repurposing of drugs by finding new therapeutic applications for medications approved for other purposes.Predictive toxicology is another area where AI is having a major impact. By predicting probable toxicities and side effects of drug candidates using AI, late-stage failures are reduced and patient safety ensured. AI is also reshaping trial methodology and patient recruiting in clinical trials, reducing costs and improving success rates.AI also helps the pharmaceutical industry deal with increasingly complicated regulatory environments by deciphering and analyzing regulatory documents and recommendations to ensure conformity with ever-changing norms. This capacity accelerates the regulatory approval process, allowing the introduction of new pharmaceuticals to the market.Despite the challenges, AI has had far-reaching and complex effects on the pharmaceutical industry. With the help of AI, the pharmaceutical industry can speed up the discovery of new drug ideas, improve the effectiveness of clinical trials, streamline production, and hone its approach to market access. The payoff for patients and the pharmaceutical business could be enormous. DOI: https://doi.org/10.52783/jchr.v13.i4.1303
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.009 | 0.014 |
| Meta-epidemiology (narrow) | 0.001 | 0.000 |
| Meta-epidemiology (broad) | 0.001 | 0.001 |
| Bibliometrics | 0.003 | 0.003 |
| Science and technology studies | 0.001 | 0.011 |
| Scholarly communication | 0.009 | 0.012 |
| Open science | 0.002 | 0.005 |
| Research integrity | 0.004 | 0.008 |
| Insufficient payload (model declined to judge) | 0.004 | 0.002 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".